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Abstract 
A rapid, sensitive and reproducible HPLC method was developed and validated 
for the analysis of memantine in human plasma after derivatization with 
o-phthaldialdehyde (OPA) and fluorescence detection. Amantadine was used 
as internal standard. The derivatized memantine and amantadine were eluted in 
less than 10 min with no interference from endogenous plasma peaks. The 
analysis was carried out on a monolithic silica column (Chromolith Performance 
RP-18e, 100×4.6 mm). The mobile phase was composed of a mixture of 
acetonitrile and 0.025 M phosphate buffer (50:50, v/v, pH=4.6) with a flow rate 
of 2.5 mLmin
−1. The excitation and emission wavelengths were set at 335 nm 
and 440 nm respectively. The assay enables the measurement of memantine 
for therapeutic drug monitoring with a lower quantification limit of 2 ngmL
−1. The 
method involves simple extraction procedure and analytical recovery was 
82.8±  0.9%. The calibration curve was linear over the concentration range   
2–80 ngmL
−1. The coefficients of variation for inter-day and intra-day assay 
were found to be less than 8%. The method was successfully applied to 
pharmacokinetic studies in humans. 848 A.  Zarghi  et al.:  
Sci Pharm. 2010; 78: 847–856. 
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Introduction 
Memantine (I, Fig. 1), 1-amino-3,5-dimethyladamantane hydrochloride, is an adamantine 
derivative administered orally for many neurologic disorders, including Alzheimer's disease 
and Parkinson [1–4]. It has been used in other disorders such as brain injury or comatose 
state. Memantine is readily absorbed from the gastro-intestinal tract with peak 
concentrations in plasma occurring ranges from 3 to 8 hours after administration by mouth. 
It is poorly metabolized by the liver and about 70% of the administered dose excreted, 
unchanged, in the urine. There have been some reports about the analysis of memantine 
determination by HPLC [5, 6], GC-MS [7, 8], and LC-MS [9–11]. However, some of these 
methods were not developed to determine memantine in plasma samples because the 
interfering endogenous substances in biological samples made the analysis more complex 
than those in preparations [5, 6], while others have either high limit of quantification (LOQ) 
or are too much complex, which limit their application for a large number of samples. 
Additionally, for the sample preparation, most of these methods require tedious extraction 
procedures, which are time-consuming, complex or both [6–10]. Moreover, some of 
aforementioned methods need long chromatographic elution time for analysis of 
memantine in plasma and were not suitable in all conditions [5, 6]. A GC/MS method has 
been also reported for determination of memantine in plasma by Kornhuber et al [8]. 
However, the method had low sensitivity (LOQ= 5 ngmL
−1) compared with LC-
fluorescence and LC-MS methods and therefore is not suitable for pharmacokinetic 
studies properties. LC methods based on MS or MS-MS as the detection system for the 
analysis of memantine in plasma are very sensitive, having low quantitation limits. 
However, these methods are not available for most laboratories because of their specialty 
requirement and financial reasons. The present study describes a rapid and sensitive 
HPLC method based on derivatization with o-phthaldialdehyde (OPA) with fluorescence 
detection, which enables the determination of memantine with good accuracy at low drug 
concentrations in plasma using simple extraction procedure. Separation was performed on 
a reversed-phase monolithic column, which has lower separation impedance comparing to 
the particulate packings, and therefore it allows easy optimizing chromatographic 
conditions to obtain desirable resolution in a short time. The sample preparation only 
involves a simple extraction procedure and no evaporation step is required. We also 
demonstrate the applicability of this method for pharmacokinetic studies in humans. 
NH2 NH2
II I  
Fig. 1.   Chemical structures of memantine I and amantadine II  
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Material and methods 
1. Chemicals 
Memantine and amantadine (II) were supplied by Osveh Pharmaceuticals (Tehran, Iran). 
Memantine is available as oral tablet containing 10 mg of memantine and other inactive 
ingredients. HPLC-grade acetonitrile and all other chemicals were obtained from Merck 
(Darmstadt, Germany). Water was obtained by double distillation and purified additionally 
with a Milli-Q system. 
2. Instruments and chromatographic conditions 
The chromatographic apparatus consisted of a model Wellchrom K-1001 pump, a model 
Rheodyne 7125 injector and a model RX-10AXL fluorescence detector connected to a 
model Eurochrom 2000 integrator, all from Knauer (Berlin, Germany). The separation was 
performed on Chromolith Performance (RP-18e, 100×4.6 mm) column from Merck 
(Darmstadt, Germany). The mobile phase consisted acetonitrile and 0.025 M phosphate 
buffer (50:50, v/v) adjusted at pH=4.6 with a flow rate of 2.5 mLmin
−1. The excitation and 
emission wavelengths were set at 335 nm and 440 nm respectively. The mobile phase 
was prepared daily and degassed by ultrasonication before use. The mobile phase was 
not allowed to recirculate during the analysis. 
3. Standard solutions 
Stock solutions (1 mgmL
−1 as the free base) of memantine hydrochloride was prepared in 
0.1 M HCl. Then 20, 100, 200, 400, 600 and 800 ngmL
−1 working standards were prepared 
in 0.01 M HCl and stored at +4 °C.  
The solution of amantadine hydrochloride, internal standard was prepared by dissolving 10 
mg amantadine hydrochloride in 10 mL 0.1 M HCl to obtain a concentration of 1 mgmL
−1. 
The final solution was obtained by diluting this solution with 0.01M HCl to give 
concentration of 500 ngmL
−1 of amantadine hydrochloride and stored at +4 °C. 
4. Sample preparation 
To 430 μL of plasma in a glass-stoppered 15 mL centrifuge tube were added 20 μL of 
amantadine as internal standard (500 ngmL
−1), 50 μL of 2.5 M NaOH solution and 100 mg 
NaCl. Then, the mixture was vortexed for 1 min and extracted with 750 μL of n-hexane. 
After mixing (30 s), the mixture centrifuged for 5 min at 8000 rpm. Then, 600 μL of organic 
phase was transferred to small-volume tube and 50 μL of 0.01 M HCl was added and 
vortexed for 1 min. The top organic layer was aspirated and discarded. To aqueous acid 
phase, 100 μL of borate buffer (0.1 M, pH= 9.5) and 200 μL of OPA derivatization solution 
(1 mL of 0.3 M OPA in methanol, 50μ μL of mercaptoethanol and 10 mL of 0.1 M borate 
buffer, pH= 9.5) were added and vortexed. The mixture was allowed to react for 1 min at 
room temperature. Then, 100 μL acetonitrile and 100 mg NaCl were added. The mixture 
was centrifuged s for 10 min at 8000 rpm and 30 μL of supernatant was injected into liquid 
chromatograph. 
5. Biological samples 
24 male healthy volunteers were included in this study. The study protocol was approved 
by the Ethics Committee of Shahid Beheshti University of Medical Sciences and written 850 A.  Zarghi  et al.:  
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informed consent was obtained from the volunteers. Memantine was administered in a 
single dose of 20 mg to the volunteers after overnight fasting. Plasma samples were 
collected at 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8,10, 24, 48 and 72 h after dosing and then frozen 
immediately at −20 °C until assayed.  
6. Stability 
The stability of memantine was assessed for spiked plasma samples stored at −20 °C for 
up to 6 months and at ambient temperature for at least 24 h. The stability of stock 
solutions stored at −20 °C was determined for up to one month by injecting appropriate 
dilutions of stocks in 0.01 HCl on day 1, 15 and 30 and comparing their peak areas with 
fresh stock prepared on the day of analysis. Samples were considered to be stable, if the 
assay values were within the acceptable limits of accuracy and precision. 
7. Plasma standard curve 
Blank plasma was prepared from heparinized whole-blood samples collected from healthy 
volunteers and stored at –20 °C. After thawing, 50 μL of one of the above-mentioned 
memantine working standards were added to yield final concentrations of 2, 10, 20, 40, 60 
and 80 ngmL
−1. Internal standard solution was added to each of these samples to yield a 
concentration of 50 ngmL
−1. The samples were then prepared for analysis as described 
above. 
Calibration curves were constructed by plotting peak area ratio (y) of memantine to the 
internal standard versus memantine concentrations (x). A linear regression was used for 
quantitation. 
8. Precision and accuracy 
The precision and accuracy of the method were examined by adding known amounts of 
memantine to pool plasma (quality control samples). For intra-day precision and accuracy 
six replicate quality control samples at each concentration were assayed on the same day. 
The inter-day precision and accuracy were evaluated on three different days. 
9. Limit of quantification (LOQ) and recovery 
For the concentration to be accepted as LOQ, the percent deviation from the nominal 
concentration (accuracy) and the relative standard deviation must be ±10% and less than 
10%, respectively, considering at least six-times the response compared to the blank 
response. The analytical recovery for plasma at four different concentrations of memantine 
(5, 20 and 60 ngmL
−1) was determined. Known amounts of memantine were added to 
drug-free plasma and the internal standard was then added. The relative recovery of 
memantine was calculated by comparing the peak areas for extracted memantine from 
spiked plasma and a standard solution of memantine in 0.01 M HCl containing internal 
standard with the same initial concentration (six samples for each concentration level).  
10. Selectivity and specificity 
Control human plasma, obtained from twelve healthy volunteers, was assessed by the 
procedure as described above and compared with respective plasma samples to evaluate 
selectivity of the method. Some antidepressant and antipsychotic drugs were tested for 
potential interferences [6].   Sensitive and Rapid HPLC Method for Determination of Memantine in Human Plasma Using …  851 
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11. Pharmacokinetic Analysis 
Memantine pharmacokinetic parameters were determined by non compartmental methods. 
Elimination rate constant (K) were estimated by the least-square regression of plasma 
concentration-time data points lying in the terminal log-linear region of the curves. Half-life 
(T1/2) was calculated as 0.693 divided by K. The area under the plasma concentration-time 
curve from time zero to the last measurable concentration at time t (AUC0-t) was calculated 
using the trapezoidal rule. The area was extrapolated to infinity (AUC0-∞) by addition of 
Ct/K to AUC0-t where Ct is the last detectable drug concentration. Peak plasma 
concentration (Cmax) and time to peak concentration (Tmax) were derived from the individual 
subject concentration- time curves. 
Results and Discussion 
Under the chromatographic conditions described, memantine and the internal standard 
peaks were well resolved. Endogenous plasma components did not give any interfering 
peaks. Separation was performed on a reversed-phase monolithic column, which has 
lower separation impedance comparing to the particulate packings, and therefore it allows 
easy optimizing chromatographic conditions to obtain desirable resolution in a short time. 
Accordingly, the chromatographic elution step is undertaken in a short time (~ 8 min) with 
high resolution. Figure 2 shows typical chromatograms of blank plasma in comparison to 
spiked samples analyzed for a pharmacokinetic study. The average retention times of 
memantine and amantadine were 4.2 and 8.1 min, respectively. The formation of the 
OPA/thiol derivatives of memantine and amantadine is simple and rapid. Reactions 
proceed to completion at room temperature in 1 min using mercaptoethanol as the 
reducing agent. The derivatization reaction depends on pH of reaction medium and it 
should be kept above pH 9.0. The repeatability of derivatization reaction was evaluated by 
relative standard deviation (RSD) of six repetitive injections of working standard solutions. 
The RSD of peak area repeatability of memantine was less than 0.5%. The derivatized 
memantine was stable enough so that re-injection of the extract the following day was 
possible using the same calibration curve. Re-injection of the memantine calibration 
standards 12 h following derivatization did not show any deterioration in peak area ratios 
(RSD < 1%) or overall sensitivity. The excitation and emission wavelengths for the 
detection of derivatized memantine and amantadine were optimized to obtain the greatest 
sensitivity under chromatographic conditions described.  
To investigate possible interference from commonly co-administered drugs, several 
antipsychotic and antidepressant drugs such as olanzepine, risperidone, clozapine, 
citalopram, fluvoxamine, fluoxetine, sertaline and bupropin were analysed under our 
chromatographic condition. None of the drugs mentioned above interfered with analytes 
peaks as well. Most of these drugs did not derivatize or elute as solvent front. For the 
sample preparation, several tedious extraction methods have been used for analysis of 
memantine in biological fluids [5–9]. In addition, some of the methods used large volumes 
of plasma samples or toxic extraction agents which limiting their application to analyze 
large numbers of clinical samples. In our method, sample preparation involves simple 
extraction procedure and no evaporation step is required. The analytical recovery for 
plasma at three different concentrations of memantine was determined. Known amounts of 
memantine were added to drug-free plasma in concentrations ranging from 5–60 ngmL
−1. 
The internal standard was added and the absolute recovery of memantine was calculated 852 A.  Zarghi  et al.:  
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by comparing the peak areas for extracted memantine from spiked plasma and a standard 
solution of memantine containing internal standard with the same initial concentration. As 
shown in Table 1. the average recovery of memantine, determined at three different 
concentrations (5, 30 and 60 ngmL
−1), was 83.2± 0.9% (n=6). The calibration curve for the 
determination of memantine in plasma was linear over the range 2–80 ngmL
−1. The 
linearity of this method was statistically confirmed. For each calibration curve, the intercept 
was not statistically different from zero. The correlation coefficients (r) for calibration 
curves were equal to or better than 0.995. The slops of plasma standard curves in the nine 
different preparations were practically the same (the CVs were less than 2% for the slops 
of plasma standard curves). For each point of calibration standards, the concentrations 
were recalculated from the equation of the linear regression curves (Table 2). Using OPA 
dervatization and fluorescence detection, the limit of quantification (LOQ), as previously 
defined, was 2 ngmL
−1 for memantine, which was better than LOQ reported by GC-MS 
assay [7, 8] or the HPLC-fluorescence assay dervatized with dansyl chloride [6]. This is 
sensitive enough for drug monitoring and other purposes such as pharmacokinetic studies.  
 
Fig. 2.  Chromatograms of (A) blank plasma; (B) blank plasma spiked with 30 ngmL
−1 
memantine (1) and 50 ngmL
−1 amantadine (2, internal standard); (C) plasma 
sample from a healthy volunteer 3 h after oral administration 20 mg memantine. 
Tab. 1.   Recovery data of memantine from plasma 
Memantine spiked  
concentration 
(ngmL
−1) 
Memantine concentration 
found (n=6)  Recovery (mean ±SD)%
5 4.1  82.0±1.1 
30 25.2  84.0±0.9 
60 50.1  83.5±0.8 
 
We assessed the precision of the method by repeated analysis of plasma specimens 
containing known concentrations of memantine. As shown in Table 3, coefficients of 
variation were less than 8%, which is acceptable for the routine measurement of 
memantine. Stability was determined for spiked plasma samples under the conditions as   Sensitive and Rapid HPLC Method for Determination of Memantine in Human Plasma Using …  853 
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previously described. The results showed that the samples were stable during the 
mentioned conditions. The aim of our study was to develop a rapid and sensitive method 
for the routine analysis of biological samples in pharmacokinetic memantine research. This 
method is well suited for routine application in the clinical laboratory because of the speed 
of analysis and simple extraction procedure.  
Tab. 2.  Assay linearity 
Coefficient of the linear  
Regression analysis (r±SD) Slope±SD Intercept±SD 
Intra-assay 
n= 6 
0.9968±5.60×10
−4
RSD= 0.056% 
0.0375±0.0005
RSD= 1.33% 
0.061±0.003 
Inter-assay 
n= 9 
0.9955±6.20×10
−4
RSD= 0.062% 
0.0381±0.0006
RSD= 1.57% 
0.063±0.004 
 
Tab. 3.   Reproducibility of the analysis of memantine in human plasma (n= 6) 
Concentration added  Concentration measured (mean ±S.E.) 
(ngmL
−1)  Intra-day  Inter-day 
  5    5.21 ± 0.39 (7.5)    4.81 ± 0.68 (7.1) 
30  29.62 ± 2.14 (7.2)  27.76 ± 1.72 (6.2) 
60  61.89 ± 2.91 (4.7)  57.36 ± 0.11 (5.4) 
Values in parentheses are coefficients of variation (%). 
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Fig. 3.   Mean plasma concentration-time profile of memantine in healthy volunteers 
(n=24) after a single 20 mg memantine. 854 A.  Zarghi  et al.:  
Sci Pharm. 2010; 78: 847–856. 
Over 700 plasma samples were analyzed by this method without any significant 
loss of resolution. No change in the column efficiency and back pressure was also 
observed over the entire study time, thus proving its suitability. In this study plasma 
concentrations were determined in 24 healthy volunteers, who received 20 mg of 
memantine each. Fig 3. shows the mean plasma concentration-time profile of 
memantine. The derived pharmacokinetic parameters of 24 healthy volunteers are 
summarized in Table 4.  
Tab. 4.   Pharmacokinetic parameters of memantine in healthy volunteers (n=24) 
following a single oral dose of 20 mg of memantine 
Parameter  Result 
(mean±SD) 
Tmax (h) 
Cmax (ngmL
−1) 
 3.72±0.40 
39.51±8.72 
AUC0-t (ng.hmL
−1) 1116.55±236.59 
AUC0-∞ (ng.hmL
−1) 
Kel (h
−1) 
1262.99±263.35 
 0.029±0.001 
T1/2 (h)  23.85±1.52 
 
Conclusions 
A rapid and sensitive HPLC method has been described for analysis of memantine in 
plasma. Derivatization with OPA is very effective method for enhancing the chromato-
graphic detection of memantine and other structurally related compound such as 
amantadine. Using monolithic column, the chromatographic elution step is undertaken in a 
short time with high resolution. In addition, the use of a simple sample preparation 
procedure instead of more complex extraction procedures makes this method suitable for 
pharmacokinetic and bioequivalence studies of memantine in humans. 
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